2024 Annual Congress of the World Muscle Society Updates

CureDuchenne Shares Updates from 29^th Annual Congress of the World Muscle Society 

We’re at the 29^th Annual Congress of the World Muscle Society this week and are pleased to share updates from companies presenting on the latest advancements in Duchenne muscular dystrophy treatments. 

Here are the latest press releases: 

• Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
  
• Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society 
  
• Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases 

• Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society 

• PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society 

• Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress 

• Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress